Relaxin to help people with cardio-metabolic disease
Relaxera’s goal is to develop synthetic human Relaxin-2 for the chronic treatment of the aging heart, Heart Failure with preserved Ejection Fraction (HFpEF), impaired glucose tolerance, and for organ protection in the field of transplant medicine.
WELCOME TO RELAXERA
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.
VISION & STRATEGY
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with…
PATENTS
Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications…
OWNERS & ADVISERS
The founders of Relaxera are a community of physicians, biochemists and pharmacologists with many years of experience in research and practice.
NEWS AND EVENTS
Relaxera Receives FDA IND Clearance for Relaxin-2 in Heart Failure with Preserved Ejection Fraction and in Atrial Fibrillation and Announces European Phase II Clinical Trial Initiation in H1 2026
The FDA's clearance of Relaxera's IND application validates the company's preclinical data package and the clinical development strategy for relaxin-2 in Heart Failure with Preserved Ejection Fraction and in Atrial Fibrillation. The submission is supported by a comprehensive body of pharmacological, toxicological, and translational evidence [...]
Clinical Study “Relaxin-2 for Patients with chronic symptomatic Heart Failure”
Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin-2 in patients with heart failure. Title of the study: Synthetic human relaxin-2 for patients with chronic symptomatic heart failure with preserved and mildly reduced ejection fraction (HFpEF, HFmrEF) and [...]
Relaxera and University of Pittsburgh announce research cooperation
As of December 2017, Relaxera and the group of Prof. Guy Salama (Heart and Vascular Institute of The University of Pittsburgh) entered into a research cooperation regarding the effects of relaxin in an animal model of HFpEF (“aged rat”). The focus of this research will, [...]
COOPERATIONS AND PROJECTS
HFpEF – Heart Failure with preserved Ejection Fraction
HFpEF represents a distinct sub-entity of heart failure. Like heart failure in general, HFpEF is characterized by the inability of the heart to provide, at normal filling pressures, an output adequate to meet the physiologically varying demands of the body (Paulus 2007, The Task Force 2008). …